Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares gapped down prior to trading on Friday . The stock had previously closed at $23.05, but opened at $20.00. Dyne Therapeutics shares last traded at $18.09, with a volume of 866,512 shares trading hands.

Analyst Ratings Changes

DYN has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird started coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price for the company. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $49.91.

Dyne Therapeutics Stock Performance

The company’s fifty day moving average is $27.29 and its two-hundred day moving average is $34.15. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -5.03 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. The trade was a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the sale, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock worth $1,443,246 in the last 90 days. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. State of New Jersey Common Pension Fund D bought a new position in Dyne Therapeutics in the 3rd quarter worth $1,588,000. Seven Eight Capital LP lifted its position in shares of Dyne Therapeutics by 195.7% during the 2nd quarter. Seven Eight Capital LP now owns 53,739 shares of the company’s stock worth $1,896,000 after buying an additional 35,568 shares during the period. Jennison Associates LLC boosted its stake in Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock valued at $48,383,000 after buying an additional 19,730 shares in the last quarter. Mutual of America Capital Management LLC bought a new stake in Dyne Therapeutics in the second quarter valued at $1,724,000. Finally, RA Capital Management L.P. grew its holdings in shares of Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.